TTUHSC El Paso’s Dr. Edward Michelson Leads ACTIV-6 National Ivermectin Study

El Paso continues to emerge as a regional research hub thanks to a confluence of factors including local universities and health systems, the regional research catalyst Medical Center of the Americas Foundation (MCA) and the growing demand for Hispanic/Latino patients, investigators, and research staff. An active participant of MCA, Dr. Edward Michelson, Chairman of the Department of Emergency Medicine at Texas Tech University Health Sciences Center (TTUHSC), El Paso, now leads a major study funded by the National Institutes of Health (NIH) known as ACTIV-6. The study investigates the possible benefits of low-cost, repurposed drugs targeting COVID-19 including ivermectin, for early-onset mild-to-moderate COVID-19, as well as cromolyn, targeting severe cases involving infected lungs.

A dynamic, committed, highly impressive yet refreshingly pragmatic medical professional, Michelson emerged as a leading figure in medicine and research for this burgeoning, predominantly Hispanic/Latino border region. TrialSite Inc.’s Founder and CEO Daniel O’Connor shared about bleaker times during the pandemic declaring, “El Paso was hit hard earlier on during the pandemic...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee